Universitätsmedizin Mannheim
umm.deTotal trials
78
Active
5
Phase 3
9
Total enrollment
28,310
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| 5-Fluorouracil | — | — | — | — | — | 1 | |
| Calcium folinate | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| Docetaxel | — | — | — | — | — | 1 | |
| Oxaliplatin during radiotherapy | — | — | — | — | — | 1 | |
| 5-Fluorouracil during radiotherapy | — | — | — | — | — | 1 | |
| Temozolomide | — | — | — | — | — | 1 |
Next readouts
- 2025-11
- 2025-12
Top conditions
- Sepsis7
- Bronchial Asthma4
- Heart Failure4
- Cardiac Disease3
- Cardiac Diseases3
- Breast Cancer3
- Tumors3
- Chronic Obstructive Pulmonary Disease3
Frequently asked questions about Universitätsmedizin Mannheim
- How many clinical trials does Universitätsmedizin Mannheim have on ClinicalTrials.gov?
- Universitätsmedizin Mannheim is listed as the lead sponsor on 78 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universitätsmedizin Mannheim's trials are in Phase 3?
- 9 of Universitätsmedizin Mannheim's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does Universitätsmedizin Mannheim focus on?
- Universitätsmedizin Mannheim's most-studied conditions on ClinicalTrials.gov are Sepsis, Bronchial Asthma, Heart Failure, Cardiac Disease, Cardiac Diseases.
- When are Universitätsmedizin Mannheim's next clinical trial readouts?
- Universitätsmedizin Mannheim has 2 upcoming primary-completion readouts tracked here; the soonest is “Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme”, expected around 2025-11.